APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma

• Ulrike Rüder ^[1] ; Carsten Denkert ^[1] ; Catarina Alisa Kunze ^[1] ; Paul Jank ^[1] ; Judith Lindner ^[1] ; Korinna Jöhrens ^[1] ; Hagen Kulbe ^[1] ; Jalid Sehouli ^[1] ; Manfred Dietel ^[1] ; Elena Braicu ^[1] ; Silvia Darb-Esfahani ^[1]
  1. [1] Charité Universitätsmedizin Berlin, Germany
• Localización: Histology and histopathology: cellular and molecular biology, ISSN-e 1699-5848, ISSN 0213-3911, Vol. 34, Nº. 4, 2019, págs. 405-417
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • APOBEC3 enzymes are part of the innate immune system and they are important in retroviral defense. The number of mutations in ovarian cancer increases with rising levels of APOBEC3B mRNA. We could confirm that APOBEC3B mRNA is upregulated in ovarian cancer cell lines and in ovarian cancer tissue. We evaluated APOBEC3B expression in histologically defined subtypes of ovarian cancer to identify its influence on overall survival (OS) and progression-free survival (PFS). Tissue microarrays from 219 patients with high-grade serous (HGSC), 61 with low-grade serous (LGSC), 62 with endometrioid (EC) and 55 with clear cell (CCC) ovarian carcinoma were stained using an antibody against APOBEC3B. Real-time quantitative PCR was performed to detect APOBEC3B mRNA levels in 274 cases of HGSC, in 11 cases of LGSC, in 47 cases of EC and in 29 cases of CCC. Tumor-infiltrating lymphocytes (TILs) have been evaluated in a previous project. APOBEC3B staining was cytoplasmic as well as nuclear and both were positively correlated (P<0.001). In HGSC a trend was detectable for positive cytoplasmic staining as favorable regarding OS (P=0.283) and PFS (P=0.137). High levels of APOBEC3B mRNA were associated with prolonged PFS in HGSC in univariate analyses (P=0.043) and multivariate analyses (HR 0.55; 95% CI 0.35-0.88; P=0.012). APOBEC3B cytoplasmic staining and APOBEC3B mRNA were positively correlated with TILs. APOBEC3B in HGSC is related to an active immune infiltrate. However, there is no evidence for APOBEC3B as a clinically relevant prognostic biomarker. Histol Histopathol 34, 405-417 (2019)